Pinned
Reflecting on 2024: a category sweep of the Nobels, AI enabled clinical readouts, and the first trillion dollar pharma in sight.
We stand on the shoulders of giants. Looking to 2025: This is just the beginning. Make no small plans.
DIMENSION
@_DimensionCap
Dimension is a multistage, research oriented, investment firm partnering with companies across the frontiers of science and compute
- Congrats to Gary Glick and the entire Odyssey Therapeutics team on today’s upsized IPO! We’re thrilled to deepen our partnership with the team as they aim to redefine the standard of care for patients living with autoimmune and inflammatory diseases. endpoints.news/odyssey-raises…
- Excited to welcome @nikhilvnamburi to the investment team at Dimension!! Nikhil brings an investment background in compute / ML infrastructure to the team and will help the firm continue to expand our work in cutting-edge technology and science. In addition to his domain
- We’re thrilled to announce our partnership with the @BioRender team! As scientists, engineers, and computational biologists ourselves, we’ve been long-time users of BioRender - many of us relying on it for years to communicate complex ideas clearly and effectively. @ShizAoki +
